@johnbstanford joined a breakout session at @BIOConvention on how to align policies impacting drug development with unmet patient need, where he discussed how policy can support innovation in areas like cancer and rare diseases.

Nearly 5 million people die annually due to antibiotic resistance. Small molecule antibiotics are essential in the fight against this global health crisis. Read more in Incubate's white paper:

Small molecule companies are "not the cool kid in the class anymore," @johnbstanford told @PharmaVoice. He outlines Incubate's survey findings on how the IRA, tariffs, and NIH cuts are shaking biotech CEOs confidence -- and what that means for Washington.

Incubate submitted a comment to @USTradeRep opposing proposed MFN drug pricing policy that could reduce U.S. biotech investment, delay access to new treatments, and weaken U.S. leadership in the sector.

"We want foreign investors coming to U.S.-based companies to develop drugs for the world." @johnbstanford spoke with @FierceBiotech at this year's @BIOConvention about supporting a robust U.S. life sciences sector.

Last week, @johnbstanford joined @PunchbowlNews for a fireside chat on the future of medicine, stressing the need to sustain U.S. leadership in life sciences and boost investment in small biotechs developing lifesaving treatments.

At this year's @BIOConvention, Incubate placed an ad in the @BostonGlobe urging Congress to end the pill penalty and pass the EPIC Act. We're proud to stand with investors calling for policies that protect progress in medicine.

"Startups are being forced to make hard choices: shelve promising programs, pull back on trials or pivot away from entire classes of cutting-edge and potentially life-saving drugs." @johnbstanford in @BioSpace on why Congress must pass the EPIC Act.

"What are we going to do from a national security perspective when China has the cure for diabetes?" @johnbstanford at last week's @PunchbowlNews fireside chat, stressing that when the U.S. falls behind in biotech, it poses a risk to our medical supply chains.

The seventh edition of Incubate Shorts is here! Incubate's policy director John Guy speaks with Victoria Ford, CEO of @txhbi, about why passing the EPIC Act and opposing MFN drug pricing is critical to supporting 9200 biotech and life science companies across Texas. Watch here:

Ahead of the DOJ & FTC listening session on barriers to generic and biosimilar competition, remember that patent protections are what enable the high-risk investments necessary to discover breakthrough therapies and improve upon existing treatments.

In an op-ed for @BioSpace, Incubate's executive director @johnbstanford highlights how recent policy changes are driving investors away from biotech. He calls on Congress to pass the EPIC Act to support new treatments and restore confidence in the sector.

The sixth edition of Incubate Shorts spotlights Patrick Jordan, Managing Partner of NovaQuest Capital Management and Chairman of @MycoviaPharma, who highlights the need to foster therapeutic innovation by ending the pill penalty and strengthening IP protections. Watch here:

HHS Secretary RFK Jr. announced his support this week for fixing the pill penalty, noting it has dampened small molecule innovation. Addressing it is key to maintaining U.S. biotech leadership, investment, and research.

This morning, @johnbstanford joined @PunchbowlNews for a fireside chat on the future of medicine. He emphasized that "science is no longer the barrier" to medical progress, but that we need the political will to sustain U.S. dominance in biotech.

RT @PunchbowlNews: Now, John Stanford, Incubate’s founder and executive director, and Janis Naeve, venture partner at Cota Capital, join An….

RT @PunchbowlNews: Happening Now – The Future of Medicine: A Conversation with Rep. Greg Murphy @repgregmurphy

In the fifth edition of Incubate Shorts, @AURP Chief Strategy Officer Brian Darmody joins Incubate’s Policy Director John Guy to discuss how MFN drug pricing and indirect cost cuts could affect biotech research grants for universities. Watch their interview:

The fourth edition of Incubate Shorts is here! @johnbstanford speaks with Tim Scott, CEO of @BiocomCA, about California's thriving life sciences industry, including the need to protect the state from MFN drug pricing and the vital role of strong patient protections. See more:

Tune in tomorrow at 9 am ET for a fireside chat with @johnbstanford and @PunchbowlNews on the future of medicine and innovation. The event opens with remarks from @RepGregMurphy. Register here:

The third edition of Incubate Shorts spotlights Maria Thacker Goethe, CEO of @Georgia_BIO. In a conversation with Incubate's Policy Director, John Guy, Maria warns that adopting Most Favored Nation drug pricing could jeopardize U.S. global competitiveness. Watch the interview: